Connect with us

Health

Commission estimates the cost of Biotech Act protections at €210 million per year

SHARE:

Published

1 month ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Commission has just released a Staff Working Document (SWD) outlining its analysis in support of the Biotech Act I. The publication comes more than five months after the Commission presented its proposal in mid-December.

One of the more contentious proposals in the Act is the proposal to offer an additional one-year Supplementary Protection Certificate (SPC) extension for certain advanced therapies, on the condition that late-stage clinical trials are conducted in more than two EU member states and that at least part of the manufacturing process takes place within the EU.

While the Commission argues that the measure could strengthen Europe’s biotechnology ecosystem, critics warn that it could come at a high cost to public healthcare systems and delay patient access to cheaper biosimilar medicines.

As Europe tries to ensure the competitiveness of its biotech sector - one of few areas where Europe is still highly productive - SPCs may seem like an easy solution that does not require a direct demand on the EU’s cash-strapped national treasuries, however it's a solution that does not come without costs....

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending